Sophia Bennett has dedicated her career to monitoring and analyzing the regulatory landscape and news within the vape industry. With a keen eye for the evolving policies that shape this dynamic market, Sophia brings a critical perspective to her commentary and reports.
For decades, cannabis consumption has existed in a measurement “gray zone,” with users relying on vague terms like “joints” or “bowls” that fail to quantify actual potency. A groundbreaking study led by the University of Bath has proposed a solution: a standardized THC unit, similar to the “standard drink” metric used for alcohol. This new […]
The consumer landscape for cannabidiol (CBD) has undergone a radical transformation in recent years. Moving beyond traditional tinctures and gummies, the market has embraced inhalation as a primary delivery method. CBD e-cigarettes—or CBD vapes—have emerged as a high-profile innovation, offering a discreet, bioavailable, and customizable way to experience the potential therapeutic benefits of hemp extracts. […]
President Trump’s executive order directs the Attorney General to “complete the rulemaking process” for rescheduling marijuana to Schedule III, primarily to facilitate medical research. It does not immediately reclassify the drug or legalize recreational use, contrary to some sensationalized headlines. The order aims to close the gap between widespread medical use and the lack of […]
Prenatal cannabis exposure refers to the use of marijuana or THC-containing products by a mother during pregnancy, a practice that is becoming increasingly common yet carries significant and often underestimated risks. While the dangers of alcohol in pregnancy are widely recognized, the conversation around cannabis is filled with misinformation. As legalization spreads and usage rates […]
Czechia’s new cannabis laws, taking full effect on January 1, 2026, will legalize personal adult use, allowing home cultivation of up to three plants and possession of up to 100 grams at home. This reform builds upon decades of progressive policy, including a robust medical program that has recently expanded access by authorizing general practitioners […]
Cannabis rescheduling refers to the federal reclassification of marijuana from a Schedule I to a Schedule III controlled substance, a move initiated by President Trump’s December 18, 2025, executive order. This shift promises to fundamentally alter the financial landscape for the cannabis industry, primarily by removing the punitive tax measures of Section 280E.